Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection

• ClinicalTrials.gov Identifier: NCT01273948
• Recruitment Status: Completed
• First Posted: January 11, 2011
• Last Update Posted: February 6, 2012
• Sponsor: Peregrine Pharmaceuticals
• Information provided by (Responsible Party): Peregrine Pharmaceuticals

Tracking Information

• First Submitted Date: January 7, 2011
• First Posted Date: January 11, 2011
• Last Update Posted Date: February 6, 2012
• Study Start Date: January 2011
• Actual Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: January 10, 2011)

Reduction in Hepatitis C Virus RNA [ Time Frame: 12 weeks ]

The primary endpoint is the proportion of patients who show a greater or equal 2-log(10) IU reduction in HCV RNA level at Study Week 12 (early virological response, EVR).

• Original Primary Outcome Measures: Same as current
• Current Secondary Outcome Measures: Not Provided
• Original Secondary Outcome Measures: Not Provided
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection
• Official Title: A Randomized, Active-Control Phase II Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic Hepatitis C Virus Genotype 1 Infection

Brief Summary

This will be a randomized, open-label, active-control Phase II pilot trial of bavituximab combined with ribavirin for initial treatment of chronic HCV genotype 1 infection. Eligible patients with normal coagulation, hematological, and renal function will undergo a screening/washout period of up to 28 days, followed by randomization to receive weekly bavituximab or PEG-IFN alpha-2a therapy for 12 weeks, both with twice-daily ribavirin.

The primary endpoint of this study is the proportion of patients who show a greater than or equal to 2-log10 IU reduction in plasma HCV RNA level after 12 weeks of treatment (early virological response; EVR).

Secondary endpoints include the proportion of patients with an undetectable HCV RNA level after 12 weeks of treatment; the proportion of patients who show a reduction in HCV RNA level of greater than or equal to 2 log10 IU after 4 weeks of treatment, viral kinetics for individual patients over time, and comprehensive evaluation of the safety and tolerability of bavituximab infusion.

• Detailed Description: Primary Objective: The primary objective of this study is to assess the effect of 12 weeks of initial treatment with bavituximab versus PEG-IFN, each combined with ribavirin, on plasma HCV RNA level in patients with chronic HCV genotype 1 infection.
• Study Type: Interventional
• Study Phase: Phase 1; Phase 2
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Hepatitis C

Intervention

• Drug: Bavituximab
  1. Bavituximab 3 mg/kg given by intravenous (IV) infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or
  2. Bavituximab 0.3 mg/kg given by IV infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or
  Other Name: Bavituxmab
• Drug: Pegylated interferon (PEG-IFN)
  Pegylated interferon (PEG-IFN) alpha-2a 180 micrograms given by subcutaneous (SC) injection once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal 75 kg) divided into twice-daily doses, for 12 weeks
  Other Name: Pegasys

Study Arms

• Experimental: Bavituximab 3 mg/kg
  Bavituximab 3 mg/kg given by intravenous (IV) infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks
  Intervention: Drug: Bavituximab
• Experimental: Bavituximab 0.3 mg/kg
  Bavituximab 0.3 mg/kg given by IV infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks
  Intervention: Drug: Bavituximab
• Active Comparator: Pegylated interferon (PEG-IFN)
  Pegylated interferon (PEG-IFN) alpha-2a 180 micrograms given by subcutaneous (SC) injection once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks
  Intervention: Drug: Pegylated interferon (PEG-IFN)

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: January 10, 2011): 66
• Original Estimated Enrollment: Same as current
• Actual Study Completion Date: February 2012
• Actual Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

1. Male or female between the ages of 18 and 65 years
2. Chronic hepatitis C virus (HCV) genotype 1 infection
3. HCV RNA level >10,000 IU/mL

4. Chronic HCV infection, defined as:

   • Previous documentation of positive HCV serology (HCV antibody or RNA) at least 6 months (24 weeks) previously, or
   • Positive HCV serology (HCV antibody or RNA) with a prior remote (more than 6 months previously) risk factor for acquisition of HCV or
   • Historical biopsy consistent with chronic HCV infection

5. No clinically significant abnormalities in hematology, coagulation, or chemistry variables:

   • Hemoglobin >12 g/dL for women; >13 g/dL for men
   • Total white cell count >3000/mm3 and absolute neutrophil count >1500/mm3
   • Platelets >100,000/mm3
   • Prothrombin time (PT) and/or international normalized ratio (INR) less than or equal to 1.2 times the local upper limit of normal (ULN)
   • Conjugated (direct) bilirubin less than or equal to 1.5 times the ULN
   • Serum creatinine within normal limits
   • Thyroid-stimulating hormone (TSH) and free thyroxine (T4) within normal limits
6. Female patients: negative urine pregnancy test
7. Ability to provide informed consent

Exclusion Criteria:

1. Previous interferon-based antiviral therapy for chronic HCV infection
2. Previous treatment with known immunogenic drugs
3. Concomitant human immunodeficiency (HIV) or hepatitis B virus (HBV) infection
4. Cause of liver disease other than chronic HCV infection, such as autoimmune or alcoholic liver disease
5. Decompensated clinical liver disease, including a history of encephalopathy, bleeding esophageal or gastric varices, or ascites
6. Recipient of liver or other solid-organ transplantation
7. Evidence of clinically significant bleeding, defined as gross hematuria, hemoptysis, or gastrointestinal bleeding
8. History of bleeding diathesis or coagulopathy (eg, von Willebrand disease or hemophilia)
9. History of thromboembolic events (eg, deep-vein thrombosis [DVT] or pulmonary embolism). Previous central venous catheter-related thrombosis is acceptable if there is resolution recorded at least 12 months before enrollment.
10. Requirement for concurrent treatment with oral or parenteral anticoagulants or hormones (estrogen-containing contraceptives, hormone replacement, antiestrogen agents, progestins)
11. Condition requiring daily therapy with antiplatelet agents (eg, thienopyridines, dipyridamole, cilostazol; cardiovascular prophylaxis with aspirin is allowed) or corticosteroids
12. Investigational therapy within 28 days before the first planned dose of study drug
13. Major surgery within 28 days before the first planned dose of study drug
14. Uncontrolled intercurrent disease (eg, diabetes, hypertension, thyroid disease)
15. Ongoing angina pectoris or other symptoms of coronary artery disease (CAD); history of stroke, or transient ischemic attack (TIA)
16. History of suicidal ideation or attempt
17. Condition requiring treatment (past or current) with coumarin-type agents
18. Cardiac arrhythmia requiring medical therapy
19. Serious nonhealing wound (including wound healing by secondary intention, ulcer, or bone fracture)
20. Cancer, autoimmune disease, or any disease or concurrent therapy known to cause significant alteration in immune function (corticosteroids are allowed before study enrollment and during the study to treat an AE)
21. Female patients and female partners of male patients: pregnancy, lactation, or inability/unwillingness to practice effective contraception

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 65 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Georgia

Administrative Information

• NCT Number: NCT01273948
• Other Study ID Numbers: PPHM 1003
• Has Data Monitoring Committee: No
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: Peregrine Pharmaceuticals
• Original Responsible Party: Janet Nutthall, MPH, Peregrine Pharmaceuticals, Inc.
• Current Study Sponsor: Peregrine Pharmaceuticals
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Study Chair: Janet Nuttall, MPH; Peregrine Pharmaceuticals

• PRS Account: Peregrine Pharmaceuticals
• Verification Date: February 2012